Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NewAmsterdam Pharma Company N.V. Warrant (NAMSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NAMSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 102.59% | Avg. Invested days 29 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 3143 | Beta -0.04 | 52 Weeks Range 5.52 - 16.75 | Updated Date 03/22/2025 |
52 Weeks Range 5.52 - 16.75 | Updated Date 03/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -338.47% |
Management Effectiveness
Return on Assets (TTM) -18.19% | Return on Equity (TTM) -46.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 53941411 |
Shares Outstanding - | Shares Floating 53941411 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Warrant
Company Overview
History and Background
NewAmsterdam Pharma, now part of Madrigal Pharmaceuticals, was focused on developing therapies for cardiometabolic diseases. Originally founded to develop obicetrapib, its history is intertwined with clinical trials and corporate strategies related to this drug.
Core Business Areas
- Cardiometabolic Disease Therapies: Focused on developing and commercializing therapies for cardiometabolic diseases, particularly those related to cholesterol management.
Leadership and Structure
After aquisition, the leadership and organizational structure has been integrated into Madrigal Pharmaceuticals.
Top Products and Market Share
Key Offerings
- Obicetrapib: Obicetrapib was NewAmsterdam Pharma's primary product, a CETP inhibitor designed to lower LDL cholesterol. The company hoped it would become a leading treatment in its category. Following the acquisition by Madrigal, the future of obicetrapib is now linked to Madrigal's overall portfolio and strategy. Competitors include existing statins and other cholesterol-lowering medications from companies like Amgen and Novartis.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on cardiometabolic diseases is competitive, with established players and emerging biotech companies vying for market share.
Positioning
NewAmsterdam Pharma aimed to position obicetrapib as a novel treatment option for patients not adequately managed by existing therapies. Its success was predicated on clinical trial results and regulatory approvals, and subsequently on Madrigal's commercialization strategy.
Total Addressable Market (TAM)
The total addressable market for cholesterol-lowering drugs is significant, potentially exceeding tens of billions of dollars. NewAmsterdam Pharma aimed to capture a portion of this market with obicetrapib.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (CETP inhibition)
- Potential to significantly lower LDL cholesterol
- Experienced management team prior to acquisition
Weaknesses
- Reliance on a single product candidate (obicetrapib)
- Regulatory and clinical trial risks
- Market competition from established therapies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial data leading to regulatory approval
Threats
- Failure to obtain regulatory approval
- Competition from existing and emerging therapies
- Adverse safety profile of obicetrapib
Competitors and Market Share
Key Competitors
- AMGN
- NVS
- MRK
Competitive Landscape
The competitive landscape is dominated by large pharmaceutical companies with established cholesterol-lowering therapies. NewAmsterdam Pharma aimed to differentiate itself with a novel mechanism of action, but was ultimately acquired.
Major Acquisitions
NewAmsterdam Pharma
- Year: 2024
- Acquisition Price (USD millions): 3500
- Strategic Rationale: Madrigal acquired NewAmsterdam Pharma to bolster its portfolio with obicetrapib, a complementary treatment option for cardiovascular disease.
Growth Trajectory and Initiatives
Historical Growth: Growth was tied to clinical trial milestones and the potential commercialization of obicetrapib.
Future Projections: Future growth now dependent on Madrigal Pharmaceuticals and their strategy
Recent Initiatives: Key initiative was advancing obicetrapib through clinical trials and securing regulatory approval.
Summary
NewAmsterdam Pharma, prior to its acquisition, was a promising biotech company focused on developing therapies for cardiometabolic diseases. Its key asset, obicetrapib, had the potential to address unmet needs in cholesterol management. However, the company faced significant risks related to clinical trials, regulatory approvals, and competition. Now integrated into Madrigal Pharmaceuticals, the success of obicetrapib depends on Madrigal's commercial strategy and execution.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
MDGL
Madrigal Pharmaceuticals Inc
MDGL
Madrigal Pharmaceuticals Inc
MRK
Merck & Company Inc
MRK
Merck & Company Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Company Filings
- Press Releases
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 68 | |
Full time employees 68 | |||
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.